Please login to the form below

Not currently logged in
Email:
Password:

Genzyme

This page shows the latest Genzyme news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

Latest news

More from news
Approximately 29 fully matching, plus 178 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... 560+. AstraZeneca / Genzyme. Acquisition of R&D. Caprelsa (vandetanib) marketed. 300.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The now expanded deal grants Genzyme rights in all markets outside North America and Western Europe. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 34 partially matching documents found.

Latest from PMHub

  • Lucid Group make the cut at the PMEAs 2017

    OptiMiSe: a Multichannel Learning Platform for Clinical Behaviour Change Among Multiple Sclerosis Specialist Nurses, by Sanofi Genzyme, with support from Lucid Group.

  • Lucid celebrate big wins at PMEA 2015

    Lucid group successfully supported AbbVie and Genzyme to win two awards at last night’ s ceremony in London. ... And they celebrated with Genzyme after supporting them to win the award for launch excellence.

  • Lucid Group Communications Limited

    Celgene. CSL Behring. Eisai. Ferring Pharmaceuticals Ltd. Genzyme. Gilead. GlaxoSmithKline. Janssen.

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics